Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | TYMP | P19971 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7095050 | 1.00 | CYP2C19 (0.39) | CYP2C19HIF1ALMNATYMP | |
| SCHEMBL9735219 | 0.89 | LMNA (0.32) | CYP2C19HIF1ALMNA | |
| SCHEMBL9736246 | 0.86 | CYP2C19 (0.45) | CYP2C19HIF1ALMNA | |
| SCHEMBL8380649 | 0.84 | CYP2C19 (0.41) | CYP2C19HIF1ALMNA | |
| SCHEMBL28198605 | 0.84 | CYP2C19 (0.35) | CYP2C19HIF1ALMNA | |
| SCHEMBL27965331 | 0.83 | CYP2C19 (0.37) | CYP2C19HIF1ALMNA | |
| SCHEMBL9190900 | 0.83 | LMNA (0.33) | CYP2C19HIF1ALMNA | |
| SCHEMBL29234146 | 0.82 | LMNA (0.30) | CYP2C19HIF1ALMNA | |
| SCHEMBL1856683 | 0.81 | CYP2C19 (0.60) | CYP2C19HIF1ALMNA | |
| SCHEMBL9287744 | 0.81 | CYP2C19 (0.42) | CYP2C19HIF1ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240271295-A1 | ELECTROCHEMICAL IODINATION OF N,N'-(2,3-DIHYDROXYPROPYL)-5-HYDROXY-1,3-BENZENEDICARBOXAMIDE | BRACCO IMAGING S.P.A. (IT) | 2024-08-15 | — | — | US | claimed |
| EP-4405329-B1 | ELECTROCHEMICAL IODINATION OF N,N'-(2,3-DIHYDROXYPROPYL)-5-HYDROXY-1,3-BENZENEDICARBOXAMIDE | BRACCO IMAGING SPA (IT) | 2025-08-20 | — | — | EP | disclosed |
| EP-4405329-A1 | ELECTROCHEMICAL IODINATION OF N,N'-(2,3-DIHYDROXYPROPYL)-5-HYDROXY-1,3-BENZENEDICARBOXAMIDE | Bracco Imaging SPA (IT) | 2024-07-31 | — | — | EP | disclosed |
| WO-2023046815-A1 | ELECTROCHEMICAL IODINATION OF N,N'-(2,3-DIHYDROXYPROPYL)-5-HYDROXY-1,3-BENZENEDICARBOXAMIDE | BRACCO IMAGING SPA (IT) | 2023-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240271295-A1 | ELECTROCHEMICAL IODINATION OF N,N'-(2,3-DIHYDROXYPROPYL)-5-HYDROXY-1,3-BENZENEDICARBOXAMIDE | HAO2, HDHD5, TPO | CYP2C19 526/4885HIF1A 400/4885LMNA 1747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.